Who
Matthew Maxwell Donley
Chief Operating Officer
Company insider
Files Form 4 as: Chief Operating Officer, Aurinia Pharmaceuticals; EVP, Global HR, IT & Strategy, Sucampo Pharmaceuticals.
In numbers
- Trades disclosed
- 48
- Buys
- 2
- Sells
- 4
- Bought
- $146K
- Sold
- $1.3M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 4 Mar 2015
- Last trade
- 2 Mar 2026
- Last filed
- 3 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Mar 2026filed 3 Mar 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $579K40,761 at $14.21 | filing |
| 2 Mar 2026filed 3 Mar 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $579K40,761 at $14.21 | filing |
| 27 Feb 2026filed 3 Mar 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —58,160 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | AUPH Aurinia Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —97,256 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | AUPH Aurinia Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —97,256 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —58,160 at $0.00 | filing |
| 20 Feb 2026filed 23 Feb 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $474K32,901 at $14.40 | filing |
| 20 Feb 2026filed 23 Feb 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $474K32,901 at $14.40 | filing |
| 2 Jan 2026filed 5 Jan 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —54,166 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $682K42,787 at $15.95 | filing |
| 2 Jan 2026filed 5 Jan 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —54,166 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $682K42,787 at $15.95 | filing |
| 4 Mar 2025filed 4 Mar 2025 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $467K58,991 at $7.92 | filing |
| 3 Mar 2025filed 4 Mar 2025 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —135,567 at $0.00 | filing |
| 3 Mar 2025filed 4 Mar 2025 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $527K65,902 at $8.00 | filing |
| 28 Feb 2025filed 4 Mar 2025 | AUPH Aurinia Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —126,416 at $0.00 | filing |
| 28 Feb 2025filed 4 Mar 2025 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —82,781 at $0.00 | filing |
| 6 Mar 2024filed 7 Mar 2024 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $224K40,665 at $5.51 | filing |
| 20 Feb 2024filed 22 Feb 2024 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —216,666 at $0.00 | filing |
| 2 Mar 2023filed 6 Mar 2023 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —271,134 | filing |
News
Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Cross Above Fifty Day Moving Average – Time to Sell?AUPH · tickerreport.com · 17 Oct 2026Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Crosses Above 50-Day Moving Average – Here's What HappenedAUPH · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Matthew Maxwell Donley; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.